miércoles, 6 de marzo de 2024

FDA approves first interchangeable biosimilars to Prolia and Xgeva to treat certain types of osteoporosis and prevent bone events in cancer

https://www.fda.gov/drugs/news-events-human-drugs/fda-approves-first-interchangeable-biosimilars-prolia-and-xgeva-treat-certain-types-osteoporosis-and?utm_medium=email&utm_source=govdelivery

No hay comentarios:

Publicar un comentario